Table 3.
List of the eye-related pathologies experienced by the 14 patients from the safety population not reaching monocular CDVA equal or better than 0.3 logMAR
| Case number | CDVA (logMAR) | Factors contributing to CDVA > 0.3 logMAR | |
|---|---|---|---|
| Preop. | 12 months | ||
| 1 | 0.4 | 0.6 | Diabetic macular oedema; diabetic proliferative retinopathy; clinically significant PCO requiring Nd:YAG |
| 2 | 1.0 | 0.92 | Amblyopia |
| 3 | 0.4 | 0.4 | No distinct ocular disorders despite diabetes; clinically significant PCO requiring Nd:YAG |
| 4 | 2.3 | 0.7 | Cornea guttata; macular atrophy; early stage band keratopathy |
| 5 | 1.3 | 1.3 | Retinal scar (geographic atrophy); amblyopia |
| 6 | 0.4 | 0.5 | Dry macular degeneration; geographic atrophy |
| 7 | 0.6 | 0.6 | Amblyopia; macular traction; retinoschisis |
| 8 | 0.4 | 0.5 | Dry macular degeneration; adult vitelliform maculopathy |
| 9 | 0.4 | 1.0 | Cornea guttata; ocular hypertension requesting surgical intervention (trabeculectomy) and leading to hyperaemia and hyphema |
| 10 | 0.4 | 0.4 | Glaucoma; dry macular degeneration; drusen macula; glaucomatous papilla; amblyopia |
| 11 | 0.52 | 0.34 | Epiretinal membrane |
| 12 | 0.3 | 0.4 | No distinct ocular disorders despite diabetes mellitus; clinically significant PCO requiring Nd:YAG |
| 13 | 0.6 | 0.32 | Age-related macular degeneration; transition from drusen age-related macular degeneration to neovascular wet age-related macular degeneration; corneal erosion; clinically significant PCO |
| 14 | 0.7 | 0.38 | Slight age-related macular degeneration with drusen; vitreous detachment; clinically significant PCO requiring Nd:YAG |